Korsana Therapeutics launched with $175 million in venture backing to advance an anti‑amyloid antibody program (KRSA‑028) spun out of Paragon Therapeutics. Investors include Wellington, Sanofi Ventures and a J.P. Morgan affiliate. Korsana positions the asset for a 2027 clinical start and plans to push into the crowded Alzheimer’s antibody space with a focus on blood‑brain barrier delivery and competitive differentiation. The raise underscores sustained investor appetite for Alzheimer’s immunotherapies despite recent mixed commercial performance in the category. Korsana’s backers highlighted the scientific pedigree and potential to iterate on next‑generation antibody designs; competitors and payers will watch trial design and biomarker strategies closely as Korsana advances toward first‑in‑human testing.